|
|
News Breaks | | | | March 19, 2013 | | 08:10 EDT |  | ACST, NEPT | Acasti Pharma presents preliminary data on NKPL66
Acasti Pharma (ACST), a Neptune Technologies & Bioressources (NEPT) subsidiary, announces encouraging preliminary clinical data of its "Randomized, Open-Label, Dose-Ranging, Multi-Center Trial to assess the Safety and efficacy of NKPL66 in the treatment of mild-to-high hypertriglyceridemia". In the course of planning the strategy of its phase III clinical development with CaPre, Acasti examined triglycerides data from its Open-label clinical trial.Data from 157 patients who have completed four weeks of treatment with 0.5, 1, 2 or 4 grams of CaPre per day were assessed and CaPre achieved a clinically important and statistically significant triglyceride reduction of up to 23% as compared to standard of care, after only a 4-week treatment. Moreover, a noteworthy trend indicating a dose-response relationship versus standard of care as well as clinically and statistically significant effects of doubling the doses of CaPre were observed. To date, the results of this preliminary analysis suggest that CaPre is safe and effective for the treatment of patients with triglyceride levels ranging from 200 to 500 mg/dL. | |
|
News For ACST;NEPT From The Last 14 Days Check below for free stories on ACST;NEPT the last two weeks. |
|
|
| May 15, 2013 | | 08:44 EDT | | NEPT | Neptune responds to Aker's attempts to deflect attention from patent dispute
Neptune Technologies & Bioressources announces that the United States Patent and Trademark Office recently issued a NON-FINAL Action Closing Prosecution in a re-examination of Neptune's Patent No. 8,030,348. Aker BioMarine, in yet another clear attempt to shift focus from its ongoing infringement of multiple Neptune patents, issued a press release addressing the re-examination. However Aker neglected to disclose that the USPTO's decision to reject Neptune's claims regarding composition of matter was only one procedural step in the long process of re-examination. Neptune will have the opportunity to submit additional arguments stating its position before the USPTO renders a final decision. | | | 08:20 EDT | | NEPT | Class action against Neptune Technologies dismissed
Neptune Technologies & Bioressources announces that the previously announced class action lawsuit filed against Neptune and certain of its officers on December 19, 2012 by Robbins Geller Rudman & Dowd LLP in the United States District Court for the Southern District of New York was voluntarily dismissed by the plaintiffs, without prejudice. No payment was made by any of the defendants in connection with the dismissal. | |
|
|
|
|
|
|
